Evidence map›Paper›PMID 26731746›Full record

ArticlePloS one2016

Osteopontin That Is Elevated in the Airways during COPD Impairs the Antibacterial Activity of Common Innate Antibiotics.

Anele Gela, Ravi K V Bhongir, Michiko Mori, Paul Keenan, Matthias Mörgelin, Jonas S Erjefält, Heiko Herwald, Arne Egesten, Gopinath Kasetty

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Article
  3. Microbiology spectrum · 2024
    Article
  4. Review
  5. Potential of Lactoferrin in the Treatment of Lung Diseases.Pharmaceuticals (Basel, Switzerland) · 2023
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Roundabout signaling pathway involved in the pathogenesis of COPD by integrative bioinformatics analysis.International journal of chronic obstructive pulmonary disease · 2019
    Article
  12. Article
  13. Going Fishing.Journal of innate immunity · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Anele GelaRespiratory Medicine & Allergology, Department of Clinical Sciences Lund, Lund University, SE-221 84, Lund, Sweden.
Ravi K V BhongirRespiratory Medicine & Allergology, Department of Clinical Sciences Lund, Lund University, SE-221 84, Lund, Sweden.
Michiko MoriAirway Inflammation Unit, Department of Experimental Medical Sciences, Lund University, SE-221 84, Lund, Sweden.
Paul KeenanRespiratory Medicine & Allergology, Department of Clinical Sciences Lund, Lund University, SE-221 84, Lund, Sweden.
Matthias MörgelinInfection Medicine, Department of Clinical Sciences Lund, Lund University, SE-221 84, Lund, Sweden.
Jonas S ErjefältAirway Inflammation Unit, Department of Experimental Medical Sciences, Lund University, SE-221 84, Lund, Sweden.
Heiko HerwaldInfection Medicine, Department of Clinical Sciences Lund, Lund University, SE-221 84, Lund, Sweden.
Arne EgestenRespiratory Medicine & Allergology, Department of Clinical Sciences Lund, Lund University, SE-221 84, Lund, Sweden.
Gopinath KasettyRespiratory Medicine & Allergology, Department of Clinical Sciences Lund, Lund University, SE-221 84, Lund, Sweden.
Lund University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bacterial infections of the respiratory tract contribute to exacerbations and disease progression in chronic obstructive pulmonary disease (COPD). There is also an increased risk of invasive pneumococcal disease in COPD. The underlying mechanisms are not fully understood but include impaired mucociliary clearance and structural remodeling of the airways. In addition, antimicrobial proteins that are constitutively expressed or induced during inflammatory conditions are an important part of the airway innate host defense. In the present study, we show that osteopontin (OPN), a multifunctional glycoprotein that is highly upregulated in the airways of COPD patients co-localizes with several antimicrobial proteins expressed in the airways. In vitro, OPN bound lactoferrin, secretory leukocyte peptidase inhibitor (SLPI), midkine, human beta defensin-3 (hBD-3), and thymic stromal lymphopoietin (TSLP) but showed low or no affinity for lysozyme and LL-37. Binding of OPN impaired the antibacterial activity against the important bacterial pathogens Streptococcus pneumoniae and Pseudomonas aeruginosa. Interestingly, OPN reduced lysozyme-induced killing of S. pneumoniae, a finding that could be explained by binding of OPN to the bacterial surface, thereby shielding the bacteria. A fragment of OPN generated by elastase of P. aeruginosa retained some inhibitory effect. Some antimicrobial proteins have additional functions. However, the muramidase-activity of lysozyme and the protease inhibitory function of SLPI were not affected by OPN. Taken together, OPN can contribute to the impairment of innate host defense by interfering with the function of antimicrobial proteins, thus increasing the vulnerability to acquire infections during COPD.

Indexed as

Bacterial Infectionsbeta-DefensinsCytokinesHumansLactoferrinLungMidkineOsteopontinProtein BindingPulmonary Disease, Chronic ObstructiveRespiratory Tract InfectionsSecretory Leukocyte Peptidase InhibitorStreptococcus pneumoniaeThymic Stromal LymphopoietinTreatment FailureUp-Regulationbeta-DefensinsCytokinesDEFB103A protein, humanLactoferrinMidkineOsteopontinSecretory Leukocyte Peptidase InhibitorSLPI protein, humanThymic Stromal Lymphopoietin

Identifiers

PMID26731746
PMCPMC4712133
OpenAlexW2228756597

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.